COVID-19 is an infectious disease caused by SARS-CoV2 virus. COVID-19 patients can develop a severe disease that can lead to hypoxic respiratory failure and acute respiratory distress syndrome (ARDS). Severe patients can require access to intensive care unit (ICU). Early rehabilitation is known to be effective in critically ill patients and in ARDS. Early rehabilitation is known to be effective in critically ill subjects. The role of physiotherapy in severe COVID-19 patients is still unclear and few guidelines have been proposed so far. Aim of this study is to assess efficacy of early rehabilitation for severe ICU-admitted COVID-19 patients as compared to a group that did not received physiotherapy treatment in ICU.
COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in China in December 2019 and in Italy in February 2020. A large proportion of infected people have mild clinical manifestations, whereas \>10% develop a severe disease, which could evolve into acute hypoxemic respiratory failure (AHRF) and acute respiratory distress syndrome (ARDS) requiring intensive care unit (ICU) admission. A high proportion of ICU patients need invasive mechanical ventilation (IMV) and about 50% of the ICU-admitted patients die. The median age of ICU COVID-19 patients was \<65 years and the mortality in patients aged \<63 years ranges from 15 to 20%. Early rehabilitation is safe and effective in critically ill patients and, in patients with ARDS, it helps to reduce the functional impairment due to the prolonged stay in ICU. Preliminary data suggest the implementation of early and active mobilization programs, as well as airway clearance, for patients with severe forms of COVID-19. To date, the role of respiratory physiotherapy in severe COVID-19 patients is still unclear. Aim of this study is to assess efficacy of early rehabilitation for severe ICU-admitted COVID-19 patients as compared to a group that did not recevied physiotherapy treatment in ICU. Physiotherapy efficacy is evaluated in terms of ventilator free days (VFD) during the first 30 days after neuromuscular blockade stop. Moreover, duration of ICU stay and patient functional status at ICU discharge will be evaluated.
Study Type
OBSERVATIONAL
Enrollment
244
Respiratory physiotherapy included: 1. early and functional mobilization: passive and active mobilization, muscle strengthening, improving independence in activities of daily living (ADL), sitting out of bed, standing, walking; 2. patient positioning to achieve better ventilation/perfusion ratio and gas exchange; 3. airway clearance; 4. aerosol administration; 5. invasive mechanical ventilation weaning; 6. use of non-invasive mechanical ventilation (NIMV) and continuous positive airway pressure (CPAP); 7. tracheostomy management and weaning; 8. swallowing assessment; 9. management of oxygen delivery; 10. lung expansion; 11. patient assessment and functional scale administration.
ASST Grande Ospedale Metropolitano Niguarda
Milan, Milan, Italy
Ospedale San Martino
Genova, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
APSS Provincia Autonoma di Trento Ospedale Santa Chiara
Trento, Italy
Ventilator-free days (VFD) and alive at day 28
To determine if early physiotherapy, as compared to no physiotherapy treatment, increases the number of ventilator-free days (VFD) and alive at day 28 in severe COVID-19 ICU-admitted patients.
Time frame: Up to 28 days after neuromuscular blokade stop
ICU stay duration
Mean days of ICU stay
Time frame: From ICU admission to ICU discharge; up to 60 days.
PaO2/FiO2
Mean measure of PaO2/FiO2
Time frame: At ICU discharge; up to 60 days
ICU survival rate
Number of patients that survived ICU stay
Time frame: From ICU admission until date of death from any cause, during ICU stay; up to 100 days.
hospital survival rate
Number of patients that survived hospitalization
Time frame: From ICU admission until date of death from any cause, during hospitalization
90 days survival rate
Number of patients that survived during 90 days after neuromuscular blokade stop
Time frame: From ICU admission until date of death from any cause, assessed up to 90 days after neuromuscular blokade removal
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.